Clinicopathological Characteristics of Inflammatory Myofibroblastic Tumor: A Single Center Retrospective Cohort Study

ABSTRACT Background Inflammatory myofibroblastic tumor (IMT) is a rare intermediate‐grade neoplasm. It presents a great challenge in diagnosis and treatment. This study aims to identify the clinicopathological characteristics of IMT. Methods A retrospective study was conducted, enrolling patients wi...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaoyan Si, Shafei Wu, Ruie Feng, Mengzhao Wang, Hanping Wang, Xiaotong Zhang, Li Zhang, Kaifeng Xu
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Thoracic Cancer
Subjects:
Online Access:https://doi.org/10.1111/1759-7714.15496
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850030418734088192
author Xiaoyan Si
Shafei Wu
Ruie Feng
Mengzhao Wang
Hanping Wang
Xiaotong Zhang
Li Zhang
Kaifeng Xu
author_facet Xiaoyan Si
Shafei Wu
Ruie Feng
Mengzhao Wang
Hanping Wang
Xiaotong Zhang
Li Zhang
Kaifeng Xu
author_sort Xiaoyan Si
collection DOAJ
description ABSTRACT Background Inflammatory myofibroblastic tumor (IMT) is a rare intermediate‐grade neoplasm. It presents a great challenge in diagnosis and treatment. This study aims to identify the clinicopathological characteristics of IMT. Methods A retrospective study was conducted, enrolling patients with IMT at Peking Union Medical College Hospital from January 2013 to October 2023. Clinical information, treatments, and efficacy were analyzed. Results A total of 72 patients were enrolled, including 38 men and 34 women, with a median age of 46.5 years. The most common primary site included the lung (n = 15, 20.8%), intestinal tract (n = 8, 11.1%), abdominal cavity (n = 7, 9.7%), and nasal sinus (n = 5, 6.9%). Thirty patients harbored anaplastic lymphoma kinase (ALK) fusion genes; Sixty‐five (90.3%) patients underwent surgical resection, and 11 of them had postoperative recurrence. Thirty patients received systemic therapy, including nonsteroidal anti‐inflammatory drugs (n = 1), steroids (n = 5), chemotherapy (n = 7), targeted therapy (n = 2), and immune checkpoint inhibitor (n = 1). Conclusions The most common site of IMT is the lung. Surgery is the main treatment for IMT, and postoperative adjuvant therapy for ALK‐positive patients needs to be focused. The molecular testing is essential for all patients diagnosed with IMTs. Systemic treatment needs further research.
format Article
id doaj-art-30b68a21d44543248f44c30bdda08daf
institution DOAJ
issn 1759-7706
1759-7714
language English
publishDate 2025-01-01
publisher Wiley
record_format Article
series Thoracic Cancer
spelling doaj-art-30b68a21d44543248f44c30bdda08daf2025-08-20T02:59:14ZengWileyThoracic Cancer1759-77061759-77142025-01-01161n/an/a10.1111/1759-7714.15496Clinicopathological Characteristics of Inflammatory Myofibroblastic Tumor: A Single Center Retrospective Cohort StudyXiaoyan Si0Shafei Wu1Ruie Feng2Mengzhao Wang3Hanping Wang4Xiaotong Zhang5Li Zhang6Kaifeng Xu7Department of Pulmonary and Critical Care Medicine Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College Beijing ChinaDepartment of Pathology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College Beijing ChinaDepartment of Pathology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College Beijing ChinaDepartment of Pulmonary and Critical Care Medicine Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College Beijing ChinaDepartment of Pulmonary and Critical Care Medicine Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College Beijing ChinaDepartment of Pulmonary and Critical Care Medicine Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College Beijing ChinaDepartment of Pulmonary and Critical Care Medicine Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College Beijing ChinaDepartment of Pulmonary and Critical Care Medicine Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College Beijing ChinaABSTRACT Background Inflammatory myofibroblastic tumor (IMT) is a rare intermediate‐grade neoplasm. It presents a great challenge in diagnosis and treatment. This study aims to identify the clinicopathological characteristics of IMT. Methods A retrospective study was conducted, enrolling patients with IMT at Peking Union Medical College Hospital from January 2013 to October 2023. Clinical information, treatments, and efficacy were analyzed. Results A total of 72 patients were enrolled, including 38 men and 34 women, with a median age of 46.5 years. The most common primary site included the lung (n = 15, 20.8%), intestinal tract (n = 8, 11.1%), abdominal cavity (n = 7, 9.7%), and nasal sinus (n = 5, 6.9%). Thirty patients harbored anaplastic lymphoma kinase (ALK) fusion genes; Sixty‐five (90.3%) patients underwent surgical resection, and 11 of them had postoperative recurrence. Thirty patients received systemic therapy, including nonsteroidal anti‐inflammatory drugs (n = 1), steroids (n = 5), chemotherapy (n = 7), targeted therapy (n = 2), and immune checkpoint inhibitor (n = 1). Conclusions The most common site of IMT is the lung. Surgery is the main treatment for IMT, and postoperative adjuvant therapy for ALK‐positive patients needs to be focused. The molecular testing is essential for all patients diagnosed with IMTs. Systemic treatment needs further research.https://doi.org/10.1111/1759-7714.15496anaplastic lymphoma kinasechemotherapyinflammatory myofibroblastic tumortargeted therapy
spellingShingle Xiaoyan Si
Shafei Wu
Ruie Feng
Mengzhao Wang
Hanping Wang
Xiaotong Zhang
Li Zhang
Kaifeng Xu
Clinicopathological Characteristics of Inflammatory Myofibroblastic Tumor: A Single Center Retrospective Cohort Study
Thoracic Cancer
anaplastic lymphoma kinase
chemotherapy
inflammatory myofibroblastic tumor
targeted therapy
title Clinicopathological Characteristics of Inflammatory Myofibroblastic Tumor: A Single Center Retrospective Cohort Study
title_full Clinicopathological Characteristics of Inflammatory Myofibroblastic Tumor: A Single Center Retrospective Cohort Study
title_fullStr Clinicopathological Characteristics of Inflammatory Myofibroblastic Tumor: A Single Center Retrospective Cohort Study
title_full_unstemmed Clinicopathological Characteristics of Inflammatory Myofibroblastic Tumor: A Single Center Retrospective Cohort Study
title_short Clinicopathological Characteristics of Inflammatory Myofibroblastic Tumor: A Single Center Retrospective Cohort Study
title_sort clinicopathological characteristics of inflammatory myofibroblastic tumor a single center retrospective cohort study
topic anaplastic lymphoma kinase
chemotherapy
inflammatory myofibroblastic tumor
targeted therapy
url https://doi.org/10.1111/1759-7714.15496
work_keys_str_mv AT xiaoyansi clinicopathologicalcharacteristicsofinflammatorymyofibroblastictumorasinglecenterretrospectivecohortstudy
AT shafeiwu clinicopathologicalcharacteristicsofinflammatorymyofibroblastictumorasinglecenterretrospectivecohortstudy
AT ruiefeng clinicopathologicalcharacteristicsofinflammatorymyofibroblastictumorasinglecenterretrospectivecohortstudy
AT mengzhaowang clinicopathologicalcharacteristicsofinflammatorymyofibroblastictumorasinglecenterretrospectivecohortstudy
AT hanpingwang clinicopathologicalcharacteristicsofinflammatorymyofibroblastictumorasinglecenterretrospectivecohortstudy
AT xiaotongzhang clinicopathologicalcharacteristicsofinflammatorymyofibroblastictumorasinglecenterretrospectivecohortstudy
AT lizhang clinicopathologicalcharacteristicsofinflammatorymyofibroblastictumorasinglecenterretrospectivecohortstudy
AT kaifengxu clinicopathologicalcharacteristicsofinflammatorymyofibroblastictumorasinglecenterretrospectivecohortstudy